ATE309999T1 - PLATELE ADP RECEPTOR INHIBITORS - Google Patents

PLATELE ADP RECEPTOR INHIBITORS

Info

Publication number
ATE309999T1
ATE309999T1 AT01908817T AT01908817T ATE309999T1 AT E309999 T1 ATE309999 T1 AT E309999T1 AT 01908817 T AT01908817 T AT 01908817T AT 01908817 T AT01908817 T AT 01908817T AT E309999 T1 ATE309999 T1 AT E309999T1
Authority
AT
Austria
Prior art keywords
derivatives
receptor inhibitors
adp receptor
platele
thrombosis
Prior art date
Application number
AT01908817T
Other languages
German (de)
Inventor
Robert M Scarborough
Hans-Michael Jantzen
Wolin Huang
David M Sedlock
Charles K Marlowe
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Application granted granted Critical
Publication of ATE309999T1 publication Critical patent/ATE309999T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Novel compounds of formula (I) to (VI), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I)-(VI), or a pharmaceutically acceptable salt thereof.
AT01908817T 2000-02-04 2001-02-05 PLATELE ADP RECEPTOR INHIBITORS ATE309999T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18020800P 2000-02-04 2000-02-04
US20207200P 2000-05-05 2000-05-05
US23044700P 2000-09-06 2000-09-06
PCT/US2001/003585 WO2001057037A1 (en) 2000-02-04 2001-02-05 Platelet adp receptor inhibitors

Publications (1)

Publication Number Publication Date
ATE309999T1 true ATE309999T1 (en) 2005-12-15

Family

ID=27391235

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01908817T ATE309999T1 (en) 2000-02-04 2001-02-05 PLATELE ADP RECEPTOR INHIBITORS

Country Status (10)

Country Link
US (5) US20020025961A1 (en)
EP (1) EP1257550B1 (en)
JP (2) JP4574100B2 (en)
AT (1) ATE309999T1 (en)
AU (1) AU3664401A (en)
CA (1) CA2400479C (en)
DE (1) DE60114994T2 (en)
DK (1) DK1257550T3 (en)
ES (1) ES2252193T3 (en)
WO (1) WO2001057037A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1257550T3 (en) 2000-02-04 2006-03-27 Portola Pharm Inc The platelet ADP receptor inhibitor
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
US6486034B1 (en) * 2001-07-20 2002-11-26 Taiwan Semiconductor Manufacturing Company Method of forming LDMOS device with double N-layering
AR037097A1 (en) 2001-10-05 2004-10-20 Novartis Ag ACILSULFONAMID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT
US7488739B2 (en) 2003-07-24 2009-02-10 Astellas Pharma Inc. Quinolone derivative or salt thereof
ATE448222T1 (en) * 2003-10-03 2009-11-15 Portola Pharm Inc 2,4-DIOXO-3-CHINAZOLINYLARYLSULFONYL UREAS
AU2004279809B2 (en) * 2003-10-03 2010-07-15 Portola Pharmaceuticals, Inc. Substituted isoquinolinones
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE102004039789A1 (en) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Aryl-substituted polycyclic amines, process for their preparation and their use as pharmaceuticals
CA2581638A1 (en) * 2004-09-29 2006-04-13 Portola Pharmaceuticals, Inc. Substituted 2h-1,3-benzoxazin-4(3h)-ones
MX2007008237A (en) * 2005-01-06 2007-08-17 Astrazeneca Ab Novel pyridine compounds.
CA2608116A1 (en) 2005-05-10 2006-11-16 Intermune, Inc. Method of modulating stress-activated protein kinase system
EP1904474A4 (en) * 2005-07-13 2010-06-16 Astrazeneca Ab New pyridine analogues
EP1951254B1 (en) * 2005-11-03 2012-01-04 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
TW200815426A (en) * 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
WO2008004943A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues
MX2008016557A (en) * 2006-07-04 2009-02-06 Astrazeneca Ab New pyridine analogues.
US20080009523A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New Pyridine Analogues IV
TW200833333A (en) * 2007-01-12 2008-08-16 Astrazeneca Ab New pyridine analogues
BRPI0806529A2 (en) * 2007-01-12 2014-04-22 Astrazeneca Ab COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD OF TREATMENT OF A PLATTER AGGREGATION DISORDER
US20080200448A1 (en) * 2007-01-12 2008-08-21 Astrazeneca Ab New Pyridine Analogues VIII 518
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
CL2008000090A1 (en) * 2007-07-13 2009-01-16 Astrazeneca Ab Pyridine derived compounds; pharmaceutical composition comprising said compounds; and their use as p2y 12 receptor inhibitors to treat a platelet aggravation disorder.
US7973051B2 (en) 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8759377B2 (en) * 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
LT3495367T (en) 2012-06-13 2021-02-25 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SI3578547T1 (en) 2015-02-16 2021-09-30 The University Of Queensland Sulfonylureas and related compounds and use of same
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
LT3448859T (en) 2017-03-20 2019-10-25 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
RS62910B1 (en) 2017-07-07 2022-03-31 Inflazome Ltd Novel sulfonamide carboxamide compounds
TW201910317A (en) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 Novel compound
AU2018317798A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3788046A1 (en) 2018-05-04 2021-03-10 Incyte Corporation Salts of an fgfr inhibitor
MA52494A (en) 2018-05-04 2021-03-10 Incyte Corp SOLID FORMS OF FGFR INHIBITOR AND THEIR PREPARATION PROCEDURES
BR112021005188A2 (en) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. treating sickle cell anemia with a pyruvate kinase r activating compound
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
TW202313611A (en) 2021-06-09 2023-04-01 美商英塞特公司 Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE845042C (en) * 1950-07-14 1952-07-28 Basf Ag Process for the preparation of sulfonyl urethanes, ureas or carboxylic acid amides
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6268380B1 (en) * 1993-02-19 2001-07-31 G. D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
WO1994021602A1 (en) * 1993-03-15 1994-09-29 G.D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
JPH0881442A (en) * 1994-07-14 1996-03-26 Otsuka Pharmaceut Co Ltd Cyclic amide derivative
JPH10195323A (en) * 1997-01-09 1998-07-28 Nippon Paper Ind Co Ltd New sulfonylguanidine compound and thermal recording material prepared by using the same
EP1047699A1 (en) * 1998-01-15 2000-11-02 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
DK1257550T3 (en) 2000-02-04 2006-03-27 Portola Pharm Inc The platelet ADP receptor inhibitor

Also Published As

Publication number Publication date
ES2252193T3 (en) 2006-05-16
DE60114994T2 (en) 2006-08-03
US20030162774A1 (en) 2003-08-28
US20070155719A1 (en) 2007-07-05
AU3664401A (en) 2001-08-14
DE60114994D1 (en) 2005-12-22
US20110212983A1 (en) 2011-09-01
DK1257550T3 (en) 2006-03-27
US20040147576A1 (en) 2004-07-29
WO2001057037A1 (en) 2001-08-09
AU2001236644B2 (en) 2006-05-04
CA2400479A1 (en) 2001-08-09
US6689786B2 (en) 2004-02-10
US20020025961A1 (en) 2002-02-28
US7022731B2 (en) 2006-04-04
JP2003522177A (en) 2003-07-22
CA2400479C (en) 2010-10-05
JP2010180226A (en) 2010-08-19
AU2001236644B8 (en) 2006-07-06
EP1257550B1 (en) 2005-11-16
US7678790B2 (en) 2010-03-16
EP1257550A1 (en) 2002-11-20
JP4574100B2 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
ATE309999T1 (en) PLATELE ADP RECEPTOR INHIBITORS
DE60238086D1 (en) PLATELET ADP RECEPTOR INHIBITORS
EA200801245A1 (en) [4- (6-HALOGEN-7-substituted
EA200500814A1 (en) DERIVATIVES OF PYRROPOLYMIDININE
NO20025601D0 (en) Arylmethylamine derivatives for use as tryptase inhibitors
NO20003018D0 (en) Triazinangiogenese inhibitors
TR200001279T2 (en) Poly (ADP-ribose) polymerase ("PARP") inhibitors, methods and pharmaceutical compositions for the treatment of neural and cardiovascular tissue damage.
NO20032233L (en) Synergistic compounds which include a renin inhibitor for cardiovascular diseases
EE200100487A (en) Novel Compounds and Compositions as Protease Inhibitors
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
LV12291A (en) Compound and pharmaceutical compositions for the treatment of related diseases by triptase activity
BR9811099A (en) Urokinase inhibitors
IS2125B (en) Cells-suppressing inflammatory-destroying and immunosuppressive compounds
MXPA04002785A (en) Substituted amines for the treatment of alzheimer's disease.
DK1296972T3 (en) Arylmethylamine derivatives for use as tryptase inhibitors
EE200000298A (en) Biphenylamidine derivatives, prodrug, blood coagulation inhibitor and prophylactic and therapeutic agent for thrombosis or embolism
PT1206444E (en) COMPOUNDS THAT INHIBIT TRIPTASE ACTIVITY
ES2284970T3 (en) AMINA 1,2- AND 1,3-DIOL COMPOUNDS AND ITS USE FOR THE TREATMENT OF ALZHEIMER.
DK1276722T3 (en) Naphthamidin-urokinase inhibitors
DE60004996D1 (en) AMINOTETRALINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
LV12459A (en) Compound and pharmaceutical compositions for the treatment of related diseases by triptase activity
PT1370526E (en) DIAMIDES THAT INHIBIT THE ACTIVITY OF TRIPTASE AND FACTOR XA
EP1452522A3 (en) Novel compounds and compositions as protease inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1257550

Country of ref document: EP